Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Falkenburg, J.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(4)
+
-
Other
(3)
+
-
Availability
Metadata Only
(7)
+
-
Creation Date
2010
(3)
+
-
Faculty
Leiden University Medical Center (LUMC)
(7)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(7)
+
-
Author
Falkenburg, J.
(7)
+
-
Jedema, I.
(5)
+
-
Balen, P. van
(2)
+
-
Borne, P. von dem
(2)
+
-
Halkes, C.
(2)
+
-
Halkes, C.J.
(2)
+
-
Meent, M. van de
(2)
+
-
Show more
Language
en
(7)
+
-
Search results
(1 - 7 of 7)
show grid
show list
save search
CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES
CD4 T-cells directed against mismatched HLA-DP isolated following donor CD4 T-cell infusion after allogeneic stem cell transplantation show differential tissue recognition
MODELING RESISTANCE TO TYROSINE KINASE INHIBITORS IN TEL/ABL plus ACUTE LYMPHOBLASTIC LEUKEMIA
Rabbit-derived ATG but not horse-derived ATG in the conditioning induces a post transplant in vivo imbalance between B and T cell recovery resulting in high risk of EBV-associated PTLD
INDUCTION OF GVHD BY HEMATOPOIESIS-SPECIFIC T CELLS MAY OCCUR DURING AN ONGOING PROFOUND GVL REACTION DUE TO ICAM-1 MEDIATED INDUCTION OF COLLATERAL DAMAGE
QUIESCENT LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR TREATMENT ARE NOT TARGETED BY ALLOREACTIVE T CELLS AND NK CELLS
LEUKEMIC CD52 NEGATIVE GPI DEFECTIVE CLONES ARE COMMON IN ALL, ESCAPE ALEMTUZUMAB THERAPY, BUT ARE SENSITIVE TO RITUXIMAB MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY: RATIONALE FOR COMBINATION THERAPY